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Cathelicidins are peptide components of the innate immune system of mammals. Apart from exerting a
direct antibiotic activity, they can also trigger specific defense responses in the host. Their roles in various
pathophysiological conditions have been studied, but there is a lack of published information on their
expression and activities in the context of mastitis. The aims of this study were to investigate the expression
of the bovine cathelicidins BMAP-27, BMAP-28, Bac5, and indolicidin in healthy and infected mammary tissue
and in lipopolysaccharide (LPS)-treated cells, to determine their activities against bacteria isolated from
bovine mastitis, and to examine their potentials to trigger defense responses in bovine mammary cells. The
genes were found to be upregulated in LPS-stimulated neutrophils, but not in infected quarters or epithelial
cells. All peptides showed a variably broad spectrum of activity against 28 bacterial isolates from bovine
mastitis (MIC values, 0.5 to 32 !M), some of which were antibiotic resistant. The activity of each peptide was
significantly enhanced when it was pairwise tested with the other peptides, reaching the synergy threshold when
indolicidin was present. The bactericidal activity was sensitive to milk components; BMAP-27 and -28 were
highly effective in mastitic bovine milk and inhibited in milk from healthy cows. Both peptides were also active
in whey and in blood serum and triggered the expression of tumor necrosis factor alpha (TNF-") in bovine
mammary epithelial cells. Our results indicate multiple roles for the bovine cathelicidins in mastitis, with
complementary and mutually enhanced antimicrobial activities against causative pathogens and the capacity
to activate host cells.
Antimicrobial peptides (AMPs) are evolutionarily ancient
peptide components of the innate immune system in verte-
brates, insects, and plants (55). Several different AMP families
have been identified in which peptides either derive from a
common ancestor (i.e., they belong to a gene family) or have
independently evolved similar primary or secondary structural
features (8, 48). A distinctive trait of all these peptides is their
ability to exert direct antimicrobial effects in vitro on an array
of different microbial pathogens. This often derives from the
fact that they have cationic and amphipathic structures capable
of interfering with microbial membranes.
Cathelicidins (48, 53) and defensins (37) are among the
largest and best-characterized AMP gene families in mammals.
A growing body of evidence suggests that, in addition to pro-
viding a first line of defense against invading microbes, these
AMPs also supply protection against infection by modulating
other components of the innate or adaptive immune response
(20, 51) and by promoting wound healing (39). In humans,
cathelicidin and defensin members have been detected in both
phagocytic and epithelial cells (37, 52) and are therefore
thought to contribute substantially to host defense at sites that
are in contact with the external environment. The sizes and
tissue distributions of the two families, however, differ signifi-
cantly among mammals. For instance, at least 7 distinct cathe-
licidin peptides have been described in the cow and have been
detected in myeloid-derived cells (53) but with no published
evidence to date of their presence in nonmyeloid cells. Most
other mammals, including humans, instead seem to carry one
cathelicidin gene, and in humans it is widely expressed in both
myeloid and epithelial cells (52). With respect to defensins,
three distinct defensin gene subfamilies, i.e., the !-, "- and
#-defensins, have been described in some primates, whereas
only "-defensins have been described in the cow (11). Bovine
"-defensins have been detected primarily in myeloid cells, as
well as in respiratory (10), oral (35), intestinal (44), and mam-
mary (34, 42) epithelia. Their expression in the last tissue has
suggested a role for these molecules in protecting against in-
fections, such as mastitis (34). In contrast, there is a lack of
published information on the expression or activities of cathe-
licidins in the context of mastitis.
Mastitis is an inflammatory process of the mammary gland
and is usually a consequence of microbial infection caused by
pathogens that find their way into the lumen of the gland
through the teat canal (57). It is a highly prevalent disease in
dairy cattle and the most costly for the dairy industry world-
wide, causing considerable economic losses due to decreased
quality and quantity of milk production, increased cost of treat-
ment and veterinary services, and loss of animals (36).
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To evaluate the roles of cathelicidins in mastitis, the present
study analyzed the expression and activities of representative
cathelicidin members, i.e., the alpha-helical “bovine myeloid
antimicrobial peptides” (BMAP-27 and BMAP-28), the pro-
line-rich peptide Bac5, and the tryptophan-rich peptide in-
dolicidin, in the context of this disease. Specifically, we exam-
ined their gene expression in healthy and infected bovine
mammary tissue and in resting and lipopolysaccharide (LPS)-
stimulated bovine mammary cells. Furthermore, we examined
their in vitro antimicrobial activities against bacterial isolates
obtained from cases of bovine mastitis under standard condi-
tions and under conditions that mimicked the mammary gland
environment, and addressed the mutual effect of multiple
cathelicidins that would result from neutrophil degranulation
at an inflammation site.
MATERIALS AND METHODS
Materials.Derivatized PEG-PS resins, coupling reagents for peptide synthesis,
and 9-fluorenylmethoxy carbonyl (Fmoc)-amino acids were purchased from Ap-
plied Biosystems (Foster City, CA), Novabiochem (Laufelfingel, Switzerland),
and ChemImpex (Wood Dale, IL). Peptide synthesis grade N,N-dimethylform-
amide, dichloromethane, piperidine, and high-performance liquid chromatogra-
phy (HPLC)-grade acetonitrile were from Biosolve (Valkenswaard, The Neth-
erlands). Trifluoroacetic acid and N-methylmorpholine were from Acros
Chimica (Beerse, Belgium). NCTC 135 medium was from Invitrogen (San Giu-
liano Milanese, Milan, Italy). Other media and reagents for cell cultures, includ-
ing fetal bovine serum (FBS), casein, and commercial antibiotics, were from
Sigma-Aldrich (St. Louis, MO). All other reagents were of analytical grade.
Buffers were prepared in double-glass-distilled water.
Peptides. The cathelicidin peptides BMAP-27, BMAP-28, Bac5, and indolici-
din (see Table 2) were chemically synthesized according to standard methods (2).
The "-defensin lingual antimicrobial peptide (LAP) (GVRNSQSCRRNKGICV
PIRCPGSMRQIGTCLGAQVKCCRRK), which contains three disulfide bonds,
was synthesized as a linear precursor and then oxidatively folded from high-
quality crude peptide (1). The peptides were confirmed by mass spectrometry
using a Q-STAR hybrid quadrupole time-of-flight mass spectrometer (Applied
Biosystems/MDS Sciex, Concord, ON, Canada) equipped with an electrospray
ion source. Peptide concentrations were determined in aqueous solution by
measuring their absorbance at 257 or 280 nm, taking into account the extinction
coefficients of 780.4 (Phe) at 257 nm for BMAP-27, 6,839 (Trp and Tyr) at 280
nm for BMAP-28, 1,280 (Tyr) at 280 nm for Bac5, and 27,795 (Trp) at 280 nm
for indolicidin (2). The LAP concentration was measured using the Waddell
method (50).
Bacterial strains. A total of six reference bacterial strains were used in this
study: Escherichia coliATCC 25922, Klebsiella pneumoniaeATCC 700603, Staph-
ylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Strep-
tococcus agalactiae ATCC 13813, and Streptococcus uberis ATCC 19436. Addi-
tionally, 28 bacterial isolates were collected from cases of clinical and subclinical
mastitis in dairy herds of Lombardia (Italy) and included 3 strains of S. agalactiae
and 5 strains each of E. coli, K. pneumoniae, S. aureus, S. epidermidis, and S.
uberis. The bacteria were maintained in Luria-Bertani (E. coli, K. pneumoniae, S.
aureus, and S. epidermidis) or blood agar (S. uberis and S. agalactiae) plates.
Bacterial isolates were tested against ampicillin, cefacetrile, cefoperazone,
cefquinome, penicillin, rifaximin, norfloxacin, and tylosin using a broth microdi-
lution assay in accordance with the guidelines and interpretative tables of the
Clinical and Laboratory Standards Institute (CLSI) (6). The bacteria were cul-
tured in Mueller-Hinton (MH) or brain heart infusion (BHI) broth (S. uberis) for
18 h, diluted 1:50 in fresh medium, and allowed to grow in a shaker at 37°C.
Mid-log-phase bacteria were harvested after 10 min of centrifugation at 1,000 $
g and resuspended in selected media. Bacterial density was assessed by turbidity
at 600 nm, with reference to previously determined standards.
Antibacterial assays.MIC values were determined using a broth microdilution
assay in 96-well microtiter plates, according to the CLSI guidelines. The antimi-
crobial activity was measured in MH broth with logarithmic-phase microorgan-
isms, as previously reported (2). S. uberis was assayed in BHI broth. Additive/
synergistic effects against the reference strain, E. coli ATCC 25922, were
evaluated in MH broth as described previously (29, 32). To detect MIC reduction
for each peptide when used in pairwise combinations, 2-fold serial dilutions of
one peptide were tested against 2-fold serial dilutions of each other peptide. The
dilution ranges were 0.063 to 4, 0.063 to 8, 0.032 to 2, and 0.125 to 16 %M for
BMAP-27, BMAP-28, Bac5, and indolicidin. The fractional inhibitory concen-
tration (FIC) index for combinations of two peptides was calculated according to
the following equation: FIC index& FICA' FICB& A/MICA' B/MICB, where
A and B are the MICs of drug A and drug B in the combination, MICA andMICB
are the MICs of drug A and drug B alone, and FICA and FICB are the FICs of
drug A and drug B. The FIC indices were interpreted as follows: !0.5, synergy;
0.51 to 4.0, no interaction; (4.0, antagonism (27).
The bactericidal activity was assayed using E. coli ATCC 25922. Bacteria (4 $
104 to 7 $ 104 CFU/ml) were incubated for 60 min at 37°C in the presence of
each peptide at 1$ MIC, 4$ MIC, or 8$ MIC, detected in MH broth, in each
of the following media: heat-inactivated bovine serum, raw milk from healthy
cows (healthy milk), milk from cows with clinical mastitis, bovine whey freshly
prepared from healthy milk (5), and MH broth supplemented with casein (26
mg/ml) (3) or with milk fat obtained as reported previously (16). Milk and whey
samples were pasteurized by heating them at 63°C for 30 min before use. After
incubation in the presence of peptides, the samples were serially diluted in
ice-cold physiological salt solution, and 50-%l aliquots were plated on MH agar.
After overnight incubation at 37°C, the colonies were enumerated, and the CFU
were calculated.
Mammary tissue sample collection. Quarter milk samples were collected from
the udders of 10 cows immediately after the organ was removed from the carcass.
Thereafter, tissue samples (n & 17) were collected from each mammary gland
quarter, immediately placed in RNAlater (Applied Biosystems), and stored at
)20°C. The infection status was determined by bacteriological analysis and
somatic cell counts (SCC) of quarter milk samples, following the National Mas-
titis Council guidelines (17). Briefly, an aliquot of 10 %l milk was spread on blood
agar plates; after 24 to 48 h of incubation at 37°C, the bacterial colonies were
isolated and identified by biochemical methods. Somatic cells were counted on a
Bentley Somacount 150 (Bentley Instruments, Chaska, MN).
PMN isolation and in vitro stimulation with bacterial LPS. Polymorphonu-
clear leukocytes (PMN) were purified from whole blood of freshly slaughtered
cows by differential centrifugation, followed by hypotonic lysis of the superna-
tant. The PMN were plated at 7.5 $ 106 cells/ml into 35-mm tissue culture petri
dishes and maintained in RPMI 1640 supplemented with 100 units/ml of peni-
cillin, 100 %g/ml streptomycin, and 2 mM L-glutamine in the presence of 10%
heat-inactivated FBS at 37°C in a humidified atmosphere with 5% CO2. The cells
were stimulated with 0.1 or 1 %g/ml purified LPS from E. coli serotype O111:B4
(Sigma-Aldrich). After 20 h at 37°C, cells were harvested with 350 %l of lysis
buffer (GE Healthcare Europe, GmbH, Milan, Italy) and stored at )20°C for
subsequent RNA isolation.
Bovine mammary epithelial cell cultures. BME-UV1 cells were purchased
from Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Ro-
magna and cultured at 37°C with 5% CO2 in the following medium: 40% Ham’s
F-12, 30% RPMI 1640, 20% NCTC 135, 10% FBS containing 0.1% lactose, 0.1%
lactalbumin hydrolysate, 1.2 mM glutathione, 10 %g/ml L-ascorbic acid, 1 %g/ml
hydrocortisone, 1 %g/ml insulin, 5 %g/ml transferrin, and 0.5 %g/ml progesterone.
The cells were seeded at a density of 40 $ 104 cells/ml in 24-well plates and
grown for 24 h in complete medium before stimulation. After 6 to 24 h at 37°C,
cells were harvested with lysis buffer (GE Healthcare Europe) and processed for
RNA isolation. An MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazo-
lium bromide] assay kit (Sigma-Aldrich) was used to assess cell viability accord-
ing to the manufacturer’s instructions.
Real-time PCR quantification. RNA was isolated from tissue and cell samples
using Illustra RNAspin (GE Healthcare Europe). One microgram of total RNA
was retrotranscribed using 200 units of Superscript II reverse transcriptase (In-
vitrogen) and oligo(dT) primers. Quantitative real-time PCR (qPCR) was car-
ried out for each sample in triplicate using the SYBR green fluorescent detection
system and the iCycler iQ5 (Bio-Rad Laboratories, Segrate, Italy). Each reaction
mixture (15 %l) contained 7.5 %l SYBR green Master Mix (Bio-Rad Laborato-
ries), 0.45 %l each primer at 10 %M, 5.1 %l water, and 1.5 %l of a 5-fold-diluted
cDNA product. The thermal-cycling program was 95°C for 3 min, followed by 40
cycles of 95°C for 10 s and 60°C for 30 s. Following qPCR cycles, dissociation
curves were run to assess the presence of only one product and the absence of
primer dimers. Primers for LAP and tumor necrosis factor alpha (TNF-!) (Table
1) were as previously reported (25, 40); primers for Bac5, BMAP-28, BMAP-27,
indolicidin, and the reference glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene (Table 1) were designed using IDT Primerquest software. The
abundance of specific gene transcripts was normalized in each sample relative to
that of GAPDH, and the results were expressed as normalized fold expression
relative to the control (uninfected).
Statistical analysis. Statistical differences among groups of data were analyzed
by one-way analysis of variance, followed by the Bonferroni posttest, using
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GraphPad Prism version 5.0 (GraphPad Software, Inc., San Diego, CA). In all
comparisons, a P of *0.05 was considered significant.
RESULTS
As an initial step to evaluate the roles of the bovine cathe-
licidin peptides in mammary gland infection, the expression of
selected cathelicidin family genes, i.e., Bac5, BMAP-27,
BMAP-28, and indolicidin, was analyzed by qPCR using RNA
extracted from bovine mammary gland tissue, from the bovine
mammary epithelial cell line BME-UV1, and from circulating
neutrophils. Mammary gland tissue was classified as healthy or
mastitic based on bacteriological analysis and SCC determina-
tion of quarter milk samples. The expression of a reference
"-defensin, LAP, was also examined in parallel. Originally
identified in the lingual tract (35), the LAP gene has since been
described in other bovine tissues, as well, including mammary
gland tissue (7), and has been found to be upregulated in
mastitic glands (15, 40, 42). In agreement with previously re-
ported data (40, 42), the expression of the LAP gene increased
on average by 50-fold in diseased compared to healthy tissue
samples (Fig. 1a) and by 15-fold in stimulated (24 h of incu-
bation in the presence of 10 %g/ml bacterial LPS) over un-
stimulated mammary epithelial cells (data not shown). Cathe-
licidin transcript levels corresponding to Bac5, BMAP-27, and
indolicidin were below the limit of detection in both mammary
tissue and the epithelial cells. Basal level BMAP-28 gene tran-
scription was detected in healthy and infected gland tissue and
in resting or LPS-treated epithelial cells (data not shown).
Low-level expression of all these genes was also observed in
resting neutrophils isolated from peripheral blood. However,
BMAP-27, BMAP-28, and Bac5, as well as LAP, were 4- to
8-fold upregulated in these cells after 20 h of stimulation with
LPS (Fig. 1b), as revealed by a time course analysis of antimi-
crobial gene expression.
To determine the efficacy of cathelicidins against bacterial
pathogens commonly associated with mastitis, individual pep-
tides (Table 2) were assayed in vitro against bacterial isolates
collected from cases of bovine mastitis, including contagious
(Staphylococcus aureus and Streptococcus agalactiae) and envi-
ronmental (Streptococcus uberis, Staphylococcus epidermidis,
Escherichia coli, and Klebsiella pneumoniae) species, and
against the corresponding ATCC reference bacterial strains.
Every bacterial isolate was first tested against ampicillin,
cefacetrile, cefoperazone, cefquinome, penicillin, rifaximin,
norfloxacin, and tylosin using a broth microdilution assay in
accordance with the guidelines and interpretative tables of the
CLSI (6). Of the 28 strains tested, 11 showed resistance to at
least one antibiotic. Specifically, three E. coli isolates were
resistant to rifaximin, one E. coli and all K. pneumoniae isolates
were resistant to both rifaximin and ampicillin, and two S.
epidermidis strains were resistant to tylosin.
When tested against bacterial isolates in standard bacterial
growth media, cathelicidin peptides were effective in the low
micromolar concentration range (Table 3). Indolicidin and
BMAP-27 exhibited the broadest activity spectrum, with MIC
values ranging from 0.5 to 8 %M. The activity of BMAP-28 was
generally similar to that of BMAP-27, except for S. uberis,
which was vulnerable to the latter but resistant (MIC( 32 %M
in four out of five clinical isolates) to the former peptide. Bac5
has previously been reported to be primarily active against
Gram-negative microorganisms (14). In the current study,
Bac5 also showed MIC values in the low micromolar range
against S. epidermidis among Gram-positive organisms. By
comparison, LAP was ineffective against all bacteria under the
medium conditions used (results not shown), in agreement
with the recognized salt and medium sensitivities of "-de-
fensins (13, 30). The MIC values obtained against the corre-
sponding ATCC reference bacterial strains did not differ sig-
nificantly from the range of values observed for clinical-isolate
strains, except that S. uberis ATCC 19436 was somewhat more
susceptible to BMAP-28 or Bac5 than S. uberis isolates and K.
TABLE 1. Primer pairs used in qPCR
Target
cDNA Oligonucleotides (5+–3+)
a Product
size (bp)
Accession no.
(GenBank)
LAP F: AATTCTCAAAGCTGCCGT 164 S76279.1
R: CACAGTTTCTGACTCCGC
Bac5 F: TGACTTCAAGGAGAATGGGCTG 127 L02650.1
R: ACGACGGATTGGTGGACGAAAT
BMAP-28 F: TCGGGAGTAACTTCGACATCACCT 141 X97609.1
R: GGCCCACAATTCACCCAATTCTGA
BMAP-27 F: ATGGGCTGGTGAAGCAATGTGTAG 163 X97608.1
R: TGGAGTAGCGGAATGACTGGAGAA
Indolicidin F: ACCCATCCAATGACCAGTTTGACC 177 X67340.1
R: TTCACTGTCCAGAAGCCCGAATCT
TNF-! F: CTGGTTCAGACACTCAGGTCCT 183 AF011926
R: GAGGTAAAGCCCGTCAGCA
GAPDH F: CCTGGAGAAACCTGCCAAGT 214 BC102589.1
R: GCCAAATTCATTGTCGTACCA
a F, forward; R, reverse.
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pneumoniae ATCC 700603 was more resistant to indolicidin
than the corresponding K. pneumoniae isolates (Table 4).
Cathelicidins are stored together as proforms, packed in the
cytoplasmic granules of bovine neutrophils under resting con-
ditions, and simultaneously released and processed into active
AMPs upon degranulation (54). We took into consideration
the possibility of mutual effects deriving from the presence of
multiple cathelicidin peptides at inflammation sites and as-
sayed the antimicrobial activity of each possible pairwise com-
bination against the reference strain E. coli ATCC 25922. Us-
ing the checkerboard method, we determined the FIC index as
a measure of synergy between peptides. The MIC values of
individual peptides against E. coli ATCC 25922 in MH broth
were 0.5, 1, 2, and 4 %M, respectively, for Bac5, BMAP-27,
BMAP-28, and indolicidin. These values decreased at least
2-fold for every peptide when tested in pairwise combinations.
The corresponding FIC indices were consistently*1 (Table 5).
In particular, indolicidin showed a FIC index of 0.5, predictive
of synergy, when combined with BMAP-28 and FIC indices of
0.56 and 0.62 when combined pairwise with Bac5 and BMAP-
27. As a method control, each peptide was tested against itself
in the checkerboard assay, and the FIC indices were consis-
tently "1 (Table 5).
We next determined the bactericidal activity of each indi-
vidual peptide against E. coliATCC 25922 in bovine serum and
in healthy versus mastitic bovine milk to assess efficacy under
conditions that mimicked the mammary gland environment.
Bacterial cultures were maintained in the absence and pres-
ence of each peptide for 60 min. When tested in MH as a
reference bacterial culture broth at concentrations correspond-
ing to four times the MIC, all peptides showed CFU numbers
decreased to undetectable levels (Table 6). However, only
BMAP-27 and -28 retained substantial activity at these con-
centrations in bovine serum (Table 6), in line with the reported
ability of helix-forming AMPs to function under a wide range
of physiological conditions (45, 56).
None of the peptides exhibited bactericidal activity against
FIG. 1. (a) Expression levels of the LAP gene in mammary glands.
Tissue samples were grouped based on SCC in milk. The arithmetic
mean for each group is indicated by a horizontal line. (b) Expression
levels of antimicrobial peptide genes in bovine neutrophils incubated
in vitro for 20 h in the absence (open bars) and presence of E. coli LPS
at 0.1 %g/ml (hatched bars) or 1 %g/ml (solid bars). The gene expres-
sion levels were evaluated using qPCR and are reported as the nor-
malized fold change compared to the expression level in healthy tissue
(a) or in unstimulated cells (b). The data in panel b are the means plus
standard deviations (SD) of three independent experiments. *, P *
0.05, and ***, P * 0.001 versus unstimulated cells, as assessed by
one-way analysis of variance and the Bonferroni posthoc test.
TABLE 2. Sequences of bovine cathelicidin peptides
Peptide
designation Sequence Molecular wt
BMAP-27 GRFKRFRKKFKKLFKKLSPVIPL
LHL-NH2
3,225
BMAP-28 GGLRSLGRKILRAWKKYGPIIV
PIIRI-NH2
3,074
Bac5 RFRPPIRRPPIRPPFYPPFRPPIR
PPIFPPIRPPFRPPLGPFP-NH2
5,147
Indolicidin ILPWKWPWWPWRR-NH2 1,906
TABLE 3. Antimicrobial activities of bovine cathelicidin peptides
against bacterial isolates obtained from clinical cases
of bovine mastitis
Organism
(no. of strains)
MIC range (%M)a
BMAP-27 BMAP-28 Bac5 Indolicidin
E. coli (5) 0.5–4 4–8 0.5–1 4
K. pneumoniae (5) 1 1–2 1–4 4–8
S. aureus (5) 4–8 2–4 (32 2–8
S. epidermidis (5) 0.5–1 1–2 1–2 1–2
S. uberis (5)b 4 2–(32 16–(32 1–2
S. agalactiae (3) 4 2 4–16 1–2
a Data are means of at least four independent experiments.
b Determined in BHI broth.
TABLE 4. Antimicrobial activities of bovine cathelicidin peptides
against reference strains
Organism
MIC (%M)a
BMAP-27 BMAP-28 Bac5 Indolicidin
E. coli ATCC 25922 1 2 0.5 4
K. pneumoniae ATCC 700603 1 2 2 (32
S. aureus ATCC 25923 2 2 (32 4
S. epidermidis ATCC 12228 2 1 8 4
S. uberisb ATCC 19436 2 4 8 8
S. agalactiae ATCC 13813 2 2 4 4
a Data are means of at least four independent experiments.
b Determined in BHI broth.
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E. coli ATCC 25922 in raw milk from healthy animals, even at
concentrations that corresponded to 8 times the MIC obtained
in MH broth (Table 6), and although the association of all four
peptides at these concentrations did affect bacterial viability,
significant variations in CFU decreases (34% to 77% over
control values) were observed under these conditions in dif-
ferent milk batches (data not shown).
Quite different results were obtained when the bactericidal
activity was assayed in milk collected from six distinct cases of
acute clinical mastitis. Typically, these samples were flocculent
and exhibited an abnormal appearance, ranging from watery
and whey-like (samples a to d) to opaque and milky (samples
e and f). As shown in Fig. 2, BMAP-27 and -28 produced
virtually complete killing in the mastitic milk samples desig-
nated a to d and a significant CFU reduction in samples e and
f, while Bac5 and indolicidin retained approximately 50% to
70% activity in samples a to c.
Overall, these results denoted more favorable killing condi-
tions in mastitic than in healthy milk. We reasoned that the
inhibitory effect of healthy milk could be connected with the
known ability of hydrophobic and/or anionic molecules present
in biological fluids to bind and sequester antimicrobial pep-
tides (18, 19). Raw milk contains a high proportion of lipids
and hydrophobic and anionic substances, such as casein. The
bactericidal activities of the peptides were therefore deter-
mined in the presence of whey, which is the milk fraction
depleted of both lipid and casein. At concentrations of
BMAP-27 and -28 at which both peptides were virtually inac-
tive in raw milk (eight-fold their MIC in MH broth), they
resulted in 100% and 60% CFU reductions, respectively, in
whey (Table 6), confirming a sequestering role for these milk
components. In contrast, the activities of Bac5 and indolicidin
did not demonstrate any improvement (Table 6), further indi-
cating that these molecules exert their antimicrobial effects
under only a limited range of conditions.
To assess the separate involvement of casein and fat in
modulating antimicrobial activity, each peptide was next tested
in MH broth supplemented with 26 mg/ml casein, according to
the average casein concentration in milk, or with milk lipid
(high-fat cream separated from a given volume of fresh milk
and added to an equivalent volume of MH), at a concentration
corresponding to the MIC value in MH broth alone. BMAP-27
and -28 caused almost complete suppression of bacterial via-
bility in casein-supplemented MH broth and 70% and 32%
CFU reductions, respectively, in milk fat-supplemented MH
broth, whereas Bac5 and indolicidin were virtually ineffective
under both conditions (Table 7).
Finally, we explored the possibility that, in addition to exerting
a direct antibiotic activity, these peptides could contribute to
innate host defense through modulation of mammary epithelial
cell function. To this end, the capacities of cathelicidin peptides to
promote TNF-! gene expression in BME-UV1 cells were evalu-
ated as a paradigm of cytokine gene induction upon cell activa-
tion.
A dose-dependent increase in the expression of the TNF-!
gene was observed by qPCR analysis of cells incubated with
micromolar concentrations of either BMAP-27 or BMAP-28.
The level of transcription of this gene was increased after 6 h
and remained steady for up to 12 h of incubation (data not
shown), with the highest induction achieved within this time
interval using 2.5 %M BMAP-27 and 1 %M BMAP-28 (Fig. 3).
TABLE 5. FIC indices of bovine cathelicidin peptides against
E. coli ATCC 25922
Peptide
FIC indexa
BMAP-27 BMAP-28 Indolicidin Bac5
BMAP-27 1.00 0.75 0.62 0.75
BMAP-28 1.00 0.50 0.56
Indolicidin 2.00 0.56
Bac5 1.36
a FIC indices are representative of three independent experiments.
TABLE 6. Bactericidal activities of bovine cathelicidin peptides
against E. coli ATCC 25922 in different biological fluids
Peptide
Bacterial viability (103 CFU/ml)a
MH
brothb
Bovine
serumb
Bovine
milkc
Bovine
wheyc
Control 125 , 20 115 , 17 148, 43 119 , 8.6
BMAP-27 *0.2d *0.2d 107 , 5.2 0.8 , 0.6d
BMAP-28 *0.2d 1.5 , 1.2d 136 , 21 38 , 7.2d
Bac5 *0.2d 86.6 , 22 146, 41 124 , 17
Indolicidin *0.2d 92 , 6.4 119, 11 143 , 3.8
a The data are means , standard deviations (SD) of at least four independent
experiments.
b Sixty-minute incubation at 4$ MIC in MH broth (Table 4).
c Sixty-minute incubation at 8$ MIC.
d Statistically significant difference from control (P * 0.001) as assessed by
one-way analysis of variance and the Bonferroni posthoc test.
FIG. 2. Killing of E. coli ATCC 25922 in milk collected from cases
of clinical mastitis. Bacteria (4 $ 104 to 7 $ 104 CFU/ml) were incu-
bated in mastitic milk samples (a to f) at 37°C for 60 min in the absence
and presence of BMAP-27, BMAP-28, Bac5, or indolicidin at concen-
trations corresponding to 8$MIC detected in MH broth. The bacteria
were diluted in ice-cold physiological salt solution and plated on MH
agar. The petri dishes were incubated at 37°C for 16 to 18 h to allow
colony counts. The results are reported as percent survival relative to
untreated bacteria and are representative of two experiments with
similar results.
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In contrast, Bac5 and indolicidin failed to induce expression of
TNF-! in these cells at concentrations up to 10 %M. MTT
measurements performed in parallel revealed that the cell
viability was never lower than 96%, indicating that none of the
peptides was cytotoxic at the concentrations used for qPCR
analysis.
DISCUSSION
In this study, we investigated the regulated gene expression
of selected bovine cathelicidins and their antimicrobial effica-
cies in mastitis.
A role for AMPs in the defense system of the mammary
gland has previously been suggested by the finding that various
"-defensins, including LAP, are expressed in mammary epi-
thelial cells (34, 43) and are upregulated in naturally occurring
and experimentally induced mastitis and in epithelial cells
stimulated in vitro with bacterial membrane components (15,
40, 43). This is strong circumstantial evidence that "-defensins
might play a role in defending the mammary epithelium from
infection. We investigated an equivalent role for bovine cathe-
licidins in bacterial mastitis with a specific focus on their anti-
microbial activities under conditions that mimicked the phys-
iological milieu.
Our gene expression studies indicated that, at variance with
the LAP gene, which is induced both in mammary gland tissue
and in neutrophils following infectious stimuli, cathelicidin
genes are induced in LPS-stimulated neutrophils, but not in
infected quarters or LPS-stimulated mammary epithelial cells.
These results confirm the role of neutrophils as a major source
of cathelicidins both from granular stores and from de novo
synthesis after granule depletion. Our observations are in line
with prior data indicating that in inflamed bovine lung, the
expression of the Bac5 gene is induced in activated neutrophils
but not in airway epithelial cells (46).
Initial support for an active role of these peptides in mastitic
infection is provided by their in vitro efficacy against different
bacterial isolates from mastitis cases, including antibiotic-re-
sistant strains. In particular, we found that the alpha-helical
peptides BMAP-27 and -28, which act principally through dis-
ruption of bacterial membrane integrity (38), are effective in
vitro, not only in standard bacterial growth media, but also in
complex biological fluids, such as blood serum and whey. The
ability of BMAPs to retain activity in serum is common to
those helical AMPs that acquire this conformation only in the
presence of an anisotropic environment, such as at the bacte-
rial membrane surface, whereas they remain largely unstruc-
tured in aqueous medium at physiological salt concentrations
(38, 49). We have previously termed this type of helical peptide
F form, with reference to some helical primate cathelicidins
that behave similarly (26, 45, 56). In rarer cases, such as the
human LL-37, a helical conformation can also be induced by
physiological salts in the absence of biological membranes (A-
form helical peptides), and we have shown these to be consid-
erably more susceptible to serum or medium components (45).
Indolicidin displayed a broad activity spectrum in standard
bacterial growth media. This AMP exhibits a mechanism of
action partly based on permeabilization of bacterial mem-
branes, although there is evidence that it also acts on internal
targets, such as bacterial DNA and RNA (12, 23, 41). Instead,
Pro-rich antimicrobial peptides, such as Bac5 and Bac7, which
generally show higher selectivity for Gram-negative than for
Gram-positive organisms, have been reported to kill bacteria
without significant membrane lysis (14). Their mode of action
may rather involve internalization via specific transporters and
recognition of cytoplasmic molecular targets (9). The SbmA
transporter appears to be required for internalization of Pro-
rich cathelicidin peptides in E. coli and Salmonella enterica
serovar Typhimurium (24, 31). The finding that mutations in
the sbmA gene lead to reduced bacterial susceptibility to Pro-
rich peptides but do not affect the antimicrobial activity of
indolicidin or alpha-helical peptides (24, 31) provides clear
evidence for separate modes of action. Interestingly, no ortho-
logues of the sbmA gene have been identified in Gram-positive
species (24), which partly explains the generally lower suscep-
tibility of Gram-positive organisms to Bac5. Our current ob-
servation that this peptide inhibits the growth of the Gram-
positive strains S. epidermidis and S. agalactiae implies the
FIG. 3. Induction of the TNF-! gene in BME-UV1 cells. The cells
were incubated for 8 h in the presence of increasing concentrations of
BMAP-27 or BMAP-28. The TNF-! gene expression levels were eval-
uated using qPCR and are reported as the normalized fold change
compared to the expression level in unstimulated cells. The data are
the means , SD of three independent experiments. !, P * 0.05; !!,
P * 0.01; !!!, P * 0.001 versus unstimulated cells, as assessed by
one-way analysis of variance and the Bonferroni posthoc test.
TABLE 7. Effects of milk casein and milk lipid on the bactericidal
activities of bovine cathelicidins against E. coli ATCC 25922
Broth
Bacterial viability (103 CFU/ml)a
Control BMAP-27 BMAP-28 Bac5 Indolicidin
MH 91.3, 11.2 0d 0d 12.8 , 5.6d 0.8 , 0.4d
MH'Cb 143 , 44 0.2, 0.08d 14 , 8.2d 120 , 21 123 , 35
MH'Lc 186 , 55 56, 7e 126 , 36 184 , 50 169 , 42
a After 60 min of incubation at the MIC. The data are means , SD of at least
four independent experiments.
b MH broth supplemented with casein.
c MH broth supplemented with milk lipid.
d P * 0.001 versus control as assessed by one-way analysis of variance and the
Bonferroni posthoc test.
e P * 0.05 versus control as assessed by one-way analysis of variance and the
Bonferroni posthoc test.
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presence of an alternative/additional and as yet unidentified
molecular target(s)/transport system(s).
Given the occurrence of different mechanisms of action and
distinct molecular targets, it is likely that the simultaneous
presence of all these peptides at an inflammatory site results in
mutual potentiation of the antimicrobial activity. This may be
achieved, for instance, through faster cellular delivery of AMPs
acting on intracellular targets as a result of perturbation of
bacterial membranes by membrane-active AMPs. The occur-
rence of multiple targets would also decrease the likelihood of
microorganisms acquiring resistance to the AMPs.
In support of mutual potentiation, we showed that the ac-
tivity of each single peptide in bacterial growth medium was
significantly enhanced when it was tested in pairwise combina-
tion with other peptides, reaching the synergy threshold when
indolicidin was present. This cooperation may allow peptides
to reach active concentrations in pathophysiologically relevant
contexts. By extension, the overall antimicrobial activity is ex-
pected to increase dramatically when the entire arsenal of
antimicrobial peptides, including cathelicidins, defensins, and
other AMPs (22), is released from neutrophils, a circumstance
that likely takes place in vivo in mastitic milk following neu-
trophil recruitment and activation at sites of udder infection.
Evidence for a significant role of cathelicidins in such a
setting is provided by in vitro testing of the bactericidal activity
against E. coli ATCC 25922 in milk collected from cases of
acute mastitis. BMAPs were highly effective in all these sam-
ples, and Bac5 and indolicidin were active in some, suggesting
that the mastitic milieu is compatible with cathelicidin activity.
Conversely, none of the peptides exhibited bactericidal ef-
fects at equivalent concentrations in healthy milk; a detectable
but variable activity was observed in this fluid only when all
four cathelicidins were present in combination. The suppres-
sive effect of healthy milk may possibly serve to control unto-
ward activities of these peptides under physiological condi-
tions. Based on killing data in lipid or casein-supplemented
MH broth, we showed that this inhibitory effect is in part
related to the presence of milk lipid and casein, although our
results also indicate a differentiated susceptibility to these milk
components. Specifically, the lipid component inactivated Bac5
and indolicidin and significantly reduced the bactericidal activ-
ity of BMAP-28, but only slightly reduced that of BMAP-27,
even though the last two peptides are structurally related.
Casein inhibited Bac5 and indolicidin but neither of the helical
BMAPs. It should be emphasized, however, that these assays
were carried out in a test medium showing a relatively simple
chemical composition. By comparison, milk is a complex bio-
logical fluid, and other chemical and/or physical factors in
addition to lipid and casein likely also contribute to the inac-
tivation of cathelicidins. As a case in point, we showed that
BMAP-27, which was largely inhibited in milk and fully active
in whey, remained highly effective in casein-supplemented MH
and was only partly inhibited in lipid-supplemented MH, con-
sistent with the presence of other inactivating milk components
not analyzed in detail in this study.
The strong influence of the milk composition on the antimi-
crobial activities of cathelicidins becomes particularly relevant
when the physical and chemical properties of healthy and mas-
titic milk are compared. Mastitis causes alterations that turn
milk into a whey-like fluid with a reduced content of different
milk components, including caseins and fat (18), and this pro-
vides a more suitable environment for efficient activity of
AMPs, as confirmed by the finding that cathelicidins in general
maintained efficient activity in mastitic milk.
In addition to exerting a broad antimicrobial activity,
BMAPs were also able to effectively trigger expression of the
proinflammatory mediator TNF-! in mammary epithelial cells
at low micromolar concentrations, thus providing an important
mechanism for the stimulation of other immune responses.
The induction levels, compared to those caused by infectious
stimuli, such as LPS, were moderate. This may be an indication
that the stimulatory function of BMAPs is more along the lines
of modulation of the immune response than induction of an
acute response. The relevance of TNF-! to mastitis is sug-
gested by its increased expression in milk somatic cells after E.
coli intramammary infection (21) and by the finding that it
improves phagocytosis and killing of S. aureus by neutrophils
(33). Additionally, the cytokine promotes the recruitment of
neutrophils to infected mammary glands by inducing expres-
sion of adhesion molecules in endothelial cells (28) and stim-
ulates AMP production (37), setting up a positive loop.
Overall, our studies indicate differential roles for the bovine
cathelicidins, regarding both their direct antimicrobial activi-
ties and their capacities to activate host cells. The alpha-helical
cathelicidins BMAP-27 and -28, in particular, maintain potent
antimicrobial activity under mammary inflammatory condi-
tions and may also play roles in activation of the immune
response by stimulating the expression of cytokines, such as
TNF-!. Bac5 and indolicidin do not appear to modulate the
expression of this gene but may trigger other protective re-
sponses, such as the reported induction of interleukin 8 (IL-8)
by indolicidin (4) and stimulation of cell proliferation by Pro-
rich peptides (47). Furthermore, the simultaneous presence of
all the peptides as a result of infection may produce a far more
robust response than that of the single molecules. These dis-
tinct and complementary functions may contribute to a thor-
ough and sustained response to infection and point to a pro-
tective role of cathelicidins in bovine mastitis.
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